These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 5035811)

  • 1. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis.
    Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL
    Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 9. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.
    Leung AC; Henderson IS; Halls DJ; Dobbie JW
    Br Med J (Clin Res Ed); 1983 Apr; 286(6375):1379-81. PubMed ID: 6404468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminium sucrose biscuits in the treatment of hyperphosphataemia.
    Morgan J; Gabriel R
    J Hum Nutr; 1979 Jun; 33(3):231-2. PubMed ID: 469238
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of the control of phosphate in the progression of chronic renal failure.
    Barrientos A; Arteaga J; Rodicio JL; Alvarez Ude F; Alcazar JM; Ruilope LM
    Miner Electrolyte Metab; 1982 Mar; 7(3):127-33. PubMed ID: 7169978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
    Peacock M; Davison AM; Walker GS
    Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum-aluminum in nondialyzed chronic uremic patients before and during treatment with aluminum-containing phosphate-binding gels.
    Brahm M
    Clin Nephrol; 1986 May; 25(5):231-5. PubMed ID: 3720033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder.
    Malberti F; Surian M; Colussi G; Poggio F; Minoia C; Salvadeo A
    Kidney Int Suppl; 1988 Mar; 24():S184-5. PubMed ID: 3163047
    [No Abstract]   [Full Text] [Related]  

  • 19. Uremic osteodystrophy. The therapeutic consequences of effective control of serum phosphorus.
    Pinggera WF; Popovtzer MM
    JAMA; 1972 Dec; 222(13):1640-2. PubMed ID: 4678366
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphate-binding effects of sucralfate in patients with chronic renal failure.
    Roxe DM; Mistovich M; Barch DH
    Am J Kidney Dis; 1989 Mar; 13(3):194-9. PubMed ID: 2919600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.